Tagrisso tablets are used to treat certain types of lung cancer associated with epidermal growth factor receptor
(EGFR) mutations. They contain the active ingredient Osimertinib, which works by blocking the signals responsible for
the growth and spread of cancer cells.
The medication helps slow disease progression and reduce the spread of cancer cells throughout the body. It is used as
part of a treatment plan determined by a specialist based on the patient's genetic testing results. Tagrisso is
distinguished by its ability to target cancer cells carrying specific genetic mutations.
Components of Tagrisso
Osimertinib
Tagrisso Strengths
Film-coated tablets 40 mg, pack contains 30 tablets.
Film-coated tablets 80 mg, pack contains 30 tablets.
Uses of TAGRISSO
Treatment of non-small cell lung cancer (NSCLC) associated with EGFR mutations.
Adjuvant treatment for certain lung cancer patients after surgery.
Helping limit the spread of cancer cells.
Treatment of cases determined by the physician based on genetic testing results.
Controlling disease progression and improving the chances of treatment response.
Dosage of Tagrisso
The usual dose is once daily in most cases, or as directed by the treating physician. The tablet may be taken with or
without food according to the patient's preference. It is recommended to take the medication at the same time each day
to help maintain its effectiveness.
The dose should not be adjusted and treatment should not be discontinued without consulting a physician, as dosage
requirements may vary depending on the patient's condition and response to therapy.
Side Effects of Tagrisso
Contraindications of Tagrisso
The medication should not be used in patients with hypersensitivity to Osimertinib or any of its ingredients. Caution
is required in patients with interstitial lung disease, heart disorders, or conditions requiring close monitoring of
organ function. It should only be used under the supervision of a physician experienced in oncology treatment.
Alternatives to Tagrisso
Metoject.
Krabeva.
Eupitrexed.
Alimta.
Use During Pregnancy and Breastfeeding
This medication should not be used during pregnancy unless specifically recommended by a physician after a careful
assessment of the potential benefits and risks. Effective contraception is recommended throughout the treatment period
according to medical advice. A physician should be consulted immediately if pregnancy occurs or is suspected.
Breastfeeding is not recommended during treatment unless otherwise advised by the physician due to the possibility of
the medication passing to the infant. Patients should strictly follow all medical instructions and recommendations
regarding treatment and regular follow-up.
Storage Conditions
Store at room temperature.
Keep away from moisture and direct heat.
Store in the original package.
Keep out of reach of children.
Do not use after the expiry date.